Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of “Hold” from Brokerages

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have earned an average recommendation of “Hold” from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $59.80.

IMCR has been the subject of several research analyst reports. Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. Needham & Company LLC raised their price objective on Immunocore from $71.00 to $75.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Mizuho set a $38.00 target price on Immunocore in a research note on Thursday, February 19th. Finally, Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th.

Insider Activity

In related news, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the transaction, the insider owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. This trade represents a 50.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the completion of the transaction, the chief executive officer owned 12,343 shares in the company, valued at approximately $399,296.05. The trade was a 48.18% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 19,137 shares of company stock valued at $619,082. Corporate insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. State of New Jersey Common Pension Fund D boosted its holdings in Immunocore by 178.5% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 25,886 shares of the company’s stock valued at $940,000 after acquiring an additional 16,591 shares during the period. Frazier Life Sciences Management L.P. increased its stake in Immunocore by 27.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 384,782 shares of the company’s stock worth $12,074,000 after purchasing an additional 83,612 shares during the period. Eschler Asset Management LLP purchased a new position in Immunocore in the 2nd quarter worth approximately $1,255,000. Schroder Investment Management Group lifted its position in Immunocore by 67.6% in the second quarter. Schroder Investment Management Group now owns 109,849 shares of the company’s stock valued at $3,447,000 after purchasing an additional 44,310 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in shares of Immunocore by 100.1% during the third quarter. Candriam S.C.A. now owns 269,729 shares of the company’s stock valued at $9,799,000 after purchasing an additional 134,950 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Price Performance

Shares of NASDAQ:IMCR opened at $30.83 on Tuesday. The company’s fifty day moving average price is $31.91 and its 200-day moving average price is $33.86. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -44.04 and a beta of 0.83. Immunocore has a one year low of $23.15 and a one year high of $40.71. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.04 and a quick ratio of 4.01.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The company had revenue of $104.48 million for the quarter. On average, equities research analysts anticipate that Immunocore will post -0.94 earnings per share for the current fiscal year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.